| Species |
Human |
| Protein Construction |
Nectin-4 IgV Domain (Gly32-Leu146)
Accession # Q96NY8-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Conjugate |
Biotin |
| Purity |
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Immobilized Nectin-4 IgV Domain[Biotin], His & Avi, Human (Cat.No.: Z03829) at 0.5 μg/ml (100μl/Well) on the plate can bind Anti-Nectin-4 Antibody. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
15.8 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 16-20 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4. |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Nectin-4 is a tumor-associated antigen. It is probably involved in cell adhesion through trans-homophilic and -heterophilic interactions. Nectin-4 is overexpressed in urothelial carcinoma and several other malignancies. It is a promising target for antibody-drug conjugates (ADCs). |
| Synonyms |
EDSS1; LNIR; Nectin4; PRR4; NECTIN4; PVRL4 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
